Story
Suncorp Shares Plunge After Denying Tokio Marine Takeover Talks
Summary
The Australian insurer's stock fell 6.7% after the company officially refuted media speculation about a potential acquisition, erasing a two-day rally.
Suncorp Group Ltd. (ASX: SUN) shares tumbled on Thursday after the Australian insurer officially denied it was in takeover discussions, unwinding a sharp, two-day rally fueled by speculative media reports of a potential acquisition by Japan’s Tokio Marine.
Company Refutes Acquisition Rumors
Suncorp's stock fell 6.7% to A$18.64 after the company issued a direct statement to the market to quash the recent rumors. The disclosure came in response to a formal query from the Australian Securities Exchange (ASX) regarding a significant surge in the company's share price and trading volume earlier in the week.
"Suncorp confirms that it is not in discussions regarding a takeover and that it has not received a takeover offer," acting CEO and CFO Jeremy Robson stated. This confirmation immediately erased the merger premium that had briefly pushed the stock to a high of A$20.18 on Wednesday.
AdMarket Impact
The denial unwound gains driven entirely by media reports suggesting Suncorp executives had traveled to Tokyo for preliminary talks with Tokio Marine. The market's reaction underscores how quickly speculative value can be wiped out once officially refuted.
Suncorp's sharp decline was compounded by a broader market sell-off. The benchmark ASX 200 index fell nearly 2% to a four-month low, though Suncorp's company-specific news made it a significant underperformer on the day.
Read next
More on Stocks
Solar Demand Outlook Brightens as Power Prices Offset Costs, KB Securities Says
An analysis by KB Securities suggests the recent solar stock sell-off may be excessive, as surging electricity prices are poised to offset higher module costs and interest rates.
Zealand Pharma Stock Falls Over 11% on Obesity Drug's Side Effect Concerns
Shares of the Danish biotech firm fell sharply after Phase III trial data for its obesity drug, survodutide, revealed a high patient discontinuation rate due to side effects, overshadowing positive efficacy results.
Nikkei 225 Surges 3.43% to One-Month High, Led by Tech Stocks
Japan's benchmark Nikkei 225 index closed up 3.43% on Thursday, reaching its highest level in a month as semiconductor-related stocks posted strong gains. The rally occurred despite a broader market decline, with more stocks falling than rising on the Tokyo Stock Exchange.
European Stocks Fall as Q4 Opens with Renewed Inflation and Energy Concerns
Major European indices, including the STOXX 600 and DAX, declined as the final quarter began, weighed down by high energy prices, accelerating regional inflation, and geopolitical tensions.